The performed study has comprised a number of 60 endometrial carcinomas, prevailed from women aged in the premenstrual period, in whose cases we have followed also the appreciation of the differentiating grading as well as the various aspects in neoplasies progression. The appreciation of the differentiating grading has allowed their placing as it follows: 39 cases of endometroid carcinoma well differentiated, seven cases of endometroid carcinoma mildly differentiated and five cases of endometroid carcinoma poorly differentiated. The correlation of the differentiating grading with the stage of tumoral progression has allowed the observation of the fact that while well invasive differentiated endometroid adenocarcinoma have been limited to the level of the uterine body, mildly and poorly differentiated invasive endometroid carcinoma besides profound myometrial invasion have associated cervical invasion and metastasis in structures situated at a real distance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Molecular classification of endometrial cancer: preliminary experience from a single Portuguese academic center.
Pathol Oncol Res
September 2024
Obstetrics and Gynecology Service, Department of Surgery, Hospital da Luz Lisboa, Lisbon, Portugal.
Background: Since the seminal publication of the TCGA consortium in 2013, the molecular classification of endometrial cancer has been widely accepted as a new and powerful tool to better understand the natural history of this malignancy. Adoption of routine molecular classification around the world has been limited. We sought to demonstrate our initial experience in incorporating the four molecular subtypes for endometrioid carcinomas.
View Article and Find Full Text PDFPrevalence and size of pelvic sentinel lymph node metastases in endometrial cancer.
Eur J Cancer
September 2024
Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, Skåne University Hospital Lund, Lund University Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynaecology, Lund, Sweden. Electronic address:
Aim Of The Study: To assess the association of prevalence and size of pelvic sentinel node (SLN) metastases with risk factors in endometrial cancer (EC).
Patients And Methods: Between June 2014 and January 2024 consecutive women with a uterine confined EC undergoing robotic surgery including detection of pelvic SLNs at a University Hospital were included. An anatomically based algorithm utilizing Indocyanine green (ICG) as tracer was adhered to.
Type I or Type II Endometrial Carcinoma? Role of BRCA1 Immunohistochemistry.
Asian Pac J Cancer Prev
July 2024
Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Objectives: Investigation of diagnostic and prognostic relevance of BRCA1 immunohistochemistry (IHC) in endometrial carcinoma.
Methods: Ninty four specimens of endometrial carcinomas were evaluated. Full sections stained with hematoxylin & eosin were revaluated for assessment of tumor type, grade, myometrial, & lympho-vascular invasion (LVI).
A prospective study of endometrial histopathology in post-menopausal women in Jharkhand.
J Family Med Prim Care
May 2024
Department of Medicine, V.M.M.C and Safdarjung Hospital, New Delhi, India.
Introduction: Postmenopausal bleeding (PMB) refers to any uterine bleeding in a menopausal women. In the early menopausal years, endometrial hyperplasia, polyps and submucosal fibroids are common etiologies of post menopausal bleeding. The most common cause of postmenopausal bleeding is endometrial atrophy, comprises of 60-80%, while endometrial hyperplasia and endometrial cancer contribute to only 11% of Post menopausal bleeding.
View Article and Find Full Text PDFChromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models.
Mol Biol Rep
June 2024
Department of Medical Oncology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.
Background: The mutational status of ovarian cancer cell line IGROV-1 is inconsistent across the literature, suggestive of multiple clonal populations of the cell line. IGROV-1 has previously been categorised as an inappropriate model for high-grade serous ovarian cancer.
Methods: IGROV-1 cells were obtained from the Netherlands Cancer Institute (IGROV-1-NKI) and the MD Anderson Cancer Centre (IGROV-1-MDA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!